Insulin aspart biosimilar(Bo'ao Bio-pharmaceutical)

Primary objective: To evaluate the bioequivalence of the two preparations in healthy Chinese male subjects by using pharmacokinetic and pharmacodynamic parameters, using insulin aspart 30 injection (NovoRapid 30) produced by Novo Nordisk A/S as the reference preparation and insulin aspart 30 injection produced by Liaoning Boao Biopharmaceutical Co., Ltd. as the test preparation in a single-center, randomized, blinded, two-period, double-crossover euglycemic glucose clamp study. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese male subjects.